Asciminib: 15 agencies, 2022–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The record spans 4.1 years, opening at AWMSG (Wales) on 21 Jun 2022 and running to 2026.
PBAC (Australia) changed its position: not recommended in 2022, recommended by 2026, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for asciminib.
The file is active: 16 of 22 records date from 2023 or later.
4 distinct indication wordings are recorded for asciminib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
5 of these 22 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess asciminib, on 21 Jun 2022; CONITEC (Brazil) did not open a file until 12 Jan 2026 — a wide spread of 3.6 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 9 of 22 dated records fall in 2023 alone.
3 of the 15 agencies here assessed asciminib more than once, PBAC (Australia) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
asciminib has been through 15 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for asciminib reads 15 recommended, 3 restricted, 1 advice and 1 no benefit, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Chronic myeloid leukaemia (CML) | Recommended | source |
| G-BA (Germany) | 21 May 2026 | Scemblix — benefit assessment §35a | added benefit: considerable (hint) | source |
| HAS (France) | 22 Apr 2026 | Indication extension | SMR substantial · ASMR IV | source |
| CONITEC (Brazil) | 12 Jan 2026 | Tratamento de pacientes adultos com leucemia mieloide crônica cromossomo Philadelfphia positivo, em fase crônica, previa… | incorporated into SUS | source |
| PHARMAC (New Zealand) | 24 Apr 2025 | Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase, previously treated with two or more tyrosin… | PTAC advice: High | source |
17 further decisions for asciminib, across 13 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 12 further source documents.
Related molecules
- imatinib — divergent outcome (recommended vs other) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
Coverage: 22 decisions for asciminib from 15 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.